Medical Condition News

RSS

Penumbra adds MAX System of Reperfusion Catheters to family of aspiration thrombectomy devices

The Penumbra System family of aspiration thrombectomy devices now includes the MAX System of Reperfusion Catheters for removal of clots in patients experiencing acute ischemic stroke. The MAX System neuro-interventional devices offer a fast, simplified cerebral thrombectomy procedure with single-operator, over-the-wire delivery without the need for a large proximal balloon guide.

18 Jun 2012

Edluar for insomnia treatment receives regulatory approval in Europe

Orexo AB is pleased to report that Edluar has received regulatory approval in Europe, according to information supplied by Meda AB, Orexo's global commercial partner for the product.

18 Jun 2012

KineMed, GSK enter multi-year biomarker discovery partnership

KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc that will apply KineMed's proprietary biomarker discovery platform in therapeutic areas of interest to GSK.

18 Jun 2012

Mallinckrodt, Horizon enter co-promotion agreement for DUEXIS

Mallinckrodt, the Pharmaceuticals business of Covidien, today announced that it has entered into a co-promotion agreement with Horizon Pharma, Inc. to promote DUEXIS (ibuprofen and famotidine).

18 Jun 2012

Major advance in development of night-time automatic control device for blood glucose levels at home

Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.

18 Jun 2012

FDA clears LensAR Laser System for anterior capsulotomy

LensAR Inc., developer of the LensAR Laser System for cataract surgery, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the company's next-generation commercial system, for use in anterior capsulotomy, with and without laser phacofragmentation during cataract surgery.

18 Jun 2012

Infinity voluntarily stops saridegib Phase 2 trial for chondrosarcoma

Infinity Pharmaceuticals, Inc. today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival.

18 Jun 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

EAACI launches Food Allergy Campaign

Today the European Academy of Allergy and Clinical Immunology (EAACI) launched its Food Allergy Campaign. The purpose of the campaign is to raise awareness of the sharp increase of anaphylaxis in children, an allergic reaction that is severe and potentially life-threatening. It aims at educating the public to recognise the symptoms and its triggers, and to teach methods of how to react in case of emergency, e.g. by using an adrenaline pen.

18 Jun 2012

Is curry good for you?

There have been several news stories over the years reporting that curry may be good for us. Most of them refer to a chemical in curry, known as curcumin.

18 Jun 2012

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

NHS Supply Chain will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy radiation therapy treatment systems.

From Elekta 18 Jun 2012

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.

18 Jun 2012

Researchers identify commensal bacteria in the human intestine

Researchers at Baylor College of Medicine and Texas Children's Hospital have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Link between unconscious conflicts and conscious anxiety disorder symptoms

An experiment that Sigmund Freud could never have imagined 100 years ago may help lend scientific support for one of his key theories, and help connect it with current neuroscience.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

CAMFT offers five simple mental wellness tips to help manage stress

While managing stress can seem like an impossible goal, the California Association of Marriage and Family Therapists (CAMFT) reminds fathers to keep their mental wellness top of mind and seek help before stress leads to a larger issue, such as depression.

18 Jun 2012